Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 9/2022

26-05-2022 | Amyotrophic Lateral Sclerosis | Review Article

Medications on hypertension, hyperlipidemia, diabetes, and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis

Authors: Nan Hu, Hongyan Ji

Published in: Neurological Sciences | Issue 9/2022

Login to get access

Abstract

Objective

To investigate the association between the use of common medications on hypertension, hyperlipidemia, diabetes, and the risk of amyotrophic lateral sclerosis (ALS).

Methods

PubMed, EMBASE, OVID, and Web of Science were searched systematically until December 2021 for studies quantitatively investigating the effect of medications on hypertension, hyperlipidemia, and diabetes on the risk of ALS. We conducted a fixed-effects model or random-effects meta-analysis to calculate the summary ORs (odds ratios) and 95%CIs (confidence intervals).

Results

Regular intake of angiotensin-converting enzyme inhibitors (ACEIs) (OR: 0.81, 95%CI: 0.74, 0.89), beta-blockers (OR: 0.82, 95%CI: 0.76, 0.90), calcium-channel blockers (CCBs) (OR: 0.85, 95%CI: 0.79, 0.93), or diuretics (OR: 0.87, 95%CI: 0.81, 0.93) was inversely associated with the incidence of ALS. There was no significant association between statin use and risk of ALS (OR: 0.92, 95%CI: 0.83, 1.03). Metformin (OR: 0.83, 95%CI: 0.75, 0.93) and sulfonylureas (OR: 0.79, 95%CI:0.71, 0.89) use could significantly reduce the risk of ALS.

Conclusion

Regular use of anti-hypertensive drugs and anti-diabetes including ACEIs, beta-blockers, CCBs, diuretics, metformin, and sulfonylureas could protect against the incidence of ALS. No significant association between anti-hyperlipidemia drug use and risk of ALS was revealed. Regular medications for hypertension, hyperlipidemia, and diabetes should be recommended regardless of the diagnosis of ALS.
Appendix
Available only for authorised users
Literature
1.
2.
Visser J et al (2007) Disease course and prognostic factors of progressive muscular atrophy. Arch Neurol 64(4):522–528PubMedCrossRef
3.
Knibb JA et al (2016) A clinical tool for predicting survival in ALS. J Neurol Neurosurg Psychiatry 87(12):1361–1367PubMedCrossRef
4.
5.
Rosa Silva JP et al (2020) Quality of life and functional independence in amyotrophic lateral sclerosis: a systematic review. Neurosci Biobehav Rev 111:1–11PubMedCrossRef
6.
De Marchi F et al (2019) Depression and risk of cognitive dysfunctions in amyotrophic lateral sclerosis. Acta Neurol Scand 139(5):438–445PubMedCrossRef
7.
McElhiney MC et al (2009) Prevalence of fatigue and depression in ALS patients and change over time. J Neurol Neurosurg Psychiatry 80(10):1146–1149PubMedCrossRef
8.
Rabkin JG et al (2015) Depression and wish to die in a multicenter cohort of ALS patients. Amyotroph Lateral Scler Frontotemporal Degener 16(3–4):265–273PubMedCrossRef
9.
Thakore NJ, Lapin BR, Pioro EP (2020) Stage-specific riluzole effect in amyotrophic lateral sclerosis: a retrospective study. Amyotroph Lateral Scler Frontotemporal Degener 21(1–2):140–143PubMedCrossRef
10.
(2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16(7): 505–512
11.
Miller RG, Mitchell JD, Moore DH (2012) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012(3):Cd001447PubMedCentral
12.
Moglia C et al (2017) Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. Amyotroph Lateral Scler Frontotemporal Degener 18(7–8):590–597PubMedCrossRef
13.
Kioumourtzoglou MA et al (2015) Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol 72(8):905–911PubMedPubMedCentralCrossRef
14.
Moreau C et al (2012) Modifying effect of arterial hypertension on amyotrophic lateral sclerosis. Amyotroph Lateral Scler 13(2):194–201PubMedCrossRef
15.
Mandrioli J et al (2018) Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. Eur J Neurol 25(6):861–868PubMedCrossRef
16.
Lian L et al (2019) Environmental risk factors and amyotrophic lateral sclerosis (ALS): a case-control study of ALS in China. J Clin Neurosci 66:12–18PubMedCrossRef
17.
Freedman DM et al (2018) Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly. Amyotroph Lateral Scler Frontotemporal Degener 19(7–8):538–546PubMedCrossRef
18.
Seelen M et al (2014) Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol 261(10):1949–1956PubMedCrossRef
19.
20.
Sun H et al (2013) Therapeutic potential of N-acetyl-glucagon-like peptide-1 in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice. Cell Mol Neurobiol 33(3):347–357PubMedCrossRef
21.
Pfeiffer RM et al (2020) Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of medicare prescription drugs. Amyotroph Lateral Scler Frontotemporal Degener 21(3–4):235–245PubMedCrossRef
22.
Stroup DF et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–12PubMedCrossRef
23.
Liberati A et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700PubMedPubMedCentralCrossRef
24.
Skajaa N et al (2021) Statin initiation and risk of amyotrophic lateral sclerosis: a Danish population-based cohort study. Epidemiology
25.
Mariosa D et al (2020) Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. Eur J Neurol 27(6):1010–1016PubMedCrossRef
26.
Torrandell-Haro G et al (2020) Statin therapy and risk of Alzheimer’s and age-related neurodegenerative diseases. Alzheimers Dement (N Y) 6(1):e12108
27.
Schumacher J et al (2020) Statins, diabetes mellitus and prognosis of amyotrophic lateral sclerosis: data from 501 patients of a population-based registry in southwest Germany. Eur J Neurol 27(8):1405–1414PubMedCrossRef
28.
Diekmann K et al (2020) Impact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group. J Neurol 267(7):2130–2141PubMedCrossRef
29.
Bond L et al (2020) Associations of Patient Mood, Modulators of Quality of Life, and Pharmaceuticals with Amyotrophic Lateral Sclerosis Survival Duration. Behav Sci (Basel) 10(1)
30.
Franchi C et al (2016) Angiotensin-converting enzyme inhibitors and motor neuron disease: an unconfirmed association. Amyotroph Lateral Scler Frontotemporal Degener 17(5–6):385–388PubMedCrossRef
31.
Lin FC et al (2015) Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: a total population-based case-control study. JAMA Neurol 72(1):40–48PubMedCrossRef
32.
Qureshi M et al (2008) Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 9(6):369–374PubMedCrossRef
33.
Linden D, Diehl RR, Berlit P (1998) Reduced baroreflex sensitivity and cardiorespiratory transfer in amyotrophic lateral sclerosis. Electroencephalogr Clin Neurophysiol 109(5):387–390PubMedCrossRef
34.
Scelsa SN, Khan I (2000) Blood pressure elevations in riluzole-treated patients with amyotrophic lateral sclerosis. Eur Neurol 43(4):224–227PubMedCrossRef
35.
Armon C et al (1991) Antecedent medical diseases in patients with amyotrophic lateral sclerosis. A population-based case-controlled study in Rochester, Minn, 1925 through 1987. Arch Neurol 48(3):283–6PubMedCrossRef
36.
Pereira M et al (2021) Cardiovascular comorbidities in amyotrophic lateral sclerosis. J Neurol Sci 421:117292PubMedCrossRef
37.
Kehoe PG, Wilcock GK (2007) Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? Lancet Neurol 6(4):373–378PubMedCrossRef
38.
Philips T, Robberecht W (2011) Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol 10(3):253–263PubMedCrossRef
39.
Ravati A et al (1999) Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol 373(1):21–33PubMedCrossRef
40.
Mira ML et al (1993) Angiotensin converting enzyme inhibitors as oxygen free radical scavengers. Free Radic Res Commun 19(3):173–181PubMedCrossRef
41.
Sengul G et al (2011) Neuroprotective effect of ACE inhibitors in glutamate - induced neurotoxicity: rat neuron culture study. Turk Neurosurg 21(3):367–371PubMed
42.
Wang H et al (2011) Vitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studies. Am J Epidemiol 173(6):595–602PubMedPubMedCentralCrossRef
43.
Ohrui T et al (2004) Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 63(7):1324–1325PubMedCrossRef
44.
Reardon KA et al (2000) The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson’s disease. Aust N Z J Med 30(1):48–53PubMedCrossRef
45.
Lin SY et al (2020) Effects of β-adrenergic blockade on metabolic and inflammatory responses in a rat model of ischemic stroke. Cells 9(6)
46.
47.
Miller RG et al (1996) Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscul Disord 6(2):101–104PubMedCrossRef
48.
Miller RG et al (1996) A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve 19(4):511–515PubMedCrossRef
49.
Dorst J et al (2011) Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol 258(4):613–617PubMedCrossRef
50.
Dupuis L et al (2008) Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70(13):1004–1009PubMedCrossRef
51.
Huang R et al (2015) The serum lipid profiles of amyotrophic lateral sclerosis patients: a study from south-west China and a meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener 16(5–6):359–365PubMedCrossRef
52.
53.
Beltowski J (2010) Statins and ALS: the possible role of impaired LXR signaling. Med Sci Monit 16(3):Ra73-78PubMed
54.
Edwards IR, Star K, Kiuru A (2007) Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf 30(6):515–525PubMedCrossRef
55.
Wannarong T, Ungprasert P (2020) Diabetes mellitus is associated with a lower risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Clin Neurol Neurosurg 199:106248PubMedCrossRef
56.
57.
58.
Zu T et al (2020) Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice. Proc Natl Acad Sci U S A 117(31):18591–18599PubMedPubMedCentralCrossRef
59.
60.
61.
Metadata
Title
Medications on hypertension, hyperlipidemia, diabetes, and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis
Authors
Nan Hu
Hongyan Ji
Publication date
26-05-2022
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 9/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-022-06131-7

Other articles of this Issue 9/2022

Neurological Sciences 9/2022 Go to the issue

Original Article

Lower serum triglyceride levels linked to more severe motor performance in Parkinson’s disease

Original Article

Pure word deafness: a case report of an atypical manifestation of Alzheimer’s disease

Letter to the Editor

Myelodysplastic syndrome in an alemtuzumab-treated multiple sclerosis patient

Original Article

Multiple sclerosis in patients with hereditary spastic paraplegia: a case report and systematic review

Brief Communication

Floating aortic arch thrombus involving the left common carotid artery complicated with ischemic stroke associated with cocaine use

Original Article

Fist-Palm Test (FiPaT): a bedside motor tool to screen for global cognitive status